期刊文献+

减肥保健食品中西布曲明及其活性代谢物总量的测定 被引量:4

Determination of Total Amount of Sibutramine and Its Active Metabolites in Weight-reducing Food
下载PDF
导出
摘要 目的:建立液相色谱和液相色谱-质谱法测定减肥保健食品中西布曲明及其活性代谢物总量的检测方法。方法:在冰水浴中,样品与甲基化试剂甲醛和硼氢化钾作用,样品中西布曲明活性代谢物定量转化成西布曲明,以液相色谱和液相色谱-质谱法检测样品中西布曲明的总量。结果:本方法线性范围为10~200mg/L,回归方程为y=89.59847x-1.05361,相关系数r=0.99993,最低检出限为1mg/kg,相对标准偏差为4.5%,回收率为83%。结论:该方法简单、准确、快速,灵敏度高、选择性好,适用于减肥保健食品中西布曲明及其活性代谢物总量的测定。 Objective: To establish a HPLC and HPLC-MS method for determining the total amount of sibutramine and its active metabolites,N-desmethyl sibutramine and N-di-desmethyl sibutramine in weight-reducing food.Methods: Samples were subjected to methylation treatment with formaldehyde and potassium borohydride in ice bath in order to convert active sibutramine metabolites into sibutramine.Results: The linear range of the method was between 10 and 200 mg/L and the regression equation was y = 89.59847x-1.05361 with a correlation coefficient of 0.9999.The detection limit was 1 mg/kg.The average recovery for the total amount of sibutramine and its active metabolites was 83% with a RSD of 4.5%.Conclusion: The established method is simple,accurate and rapid and has good selectivity.It is most suitable for determining total amount of sibutramine and its active metabolites in weight-reducing food.
出处 《食品科学》 EI CAS CSCD 北大核心 2010年第14期205-208,共4页 Food Science
基金 吉林省地方标准项目(DB22/T 1163-2009)
关键词 西布曲明 活性代谢物 高效液相色谱-质谱法 减肥保健食品 sibutramine active metabolites HPLC-MS weight-reducing food
  • 相关文献

参考文献21

  • 1梁晓丽,车宁.盐酸西布曲明的研究现状[J].首都医药,2004,11(14):38-40. 被引量:6
  • 2LUQUE C A, REY J A. The discovery and status of sibutramine as an anti-obesity drug[J]. European Journal of Pharmacology, 2002, 440(2/ 3): 119-128.
  • 3TALLET A J, BLUNDELL J E, RODGERS R J. Sibutramine-induced anorexia: Potent, dose-dependent and behaviourally-selective profile in male rats[J]. Behavioural Brain Research, 2009, 198(2): 359-365.
  • 4ELFHAG K, ROSSNER S, BARKELING B, et al. Sibutramine treatment in obesity: initial eating behaviourin relation to weight loss results and changes in mood[J]. Pharmacological Research, 2005, 51 (2): 159-163.
  • 5陈洲,廖丽萍,刘礼斌.盐酸西布曲明对高脂肥胖大鼠下丘脑增食欲素系统的影响[J].中国药理学通报,2008,24(2):262-265. 被引量:3
  • 6KIORTSIS D N, TSOULI S, FILIPPATOS T D, et al. Effects of sibutramine and orlistat on mood inobese and overweight subjects: a randomised study[J]. Nutrition, Metabolism and Cardiovascular 2008, 18(3): 207-210.
  • 7MANNUCCI E, DICEMBRINI I, ROTELLA F, et al. Orlistat and sibutramine beyond weight loss[J]. Nutrition, Metabolism & Cardiovascular Diseases, 2008,18(5): 342-348.
  • 8宫斯宁,陈瀛,梅菊,吴秀玲.西布曲明的晶体合成、结构表征及其药用原理分析[J].纳米科技,2009,6(2):25-28. 被引量:1
  • 9LUQUE C A, REY J A. S ibulramine: a serotonin-norepinephrine reuptakeinhibitorfor the treatment of obesity[J]. Ann Pharmacother, 1999, 33(9): 968-978.
  • 10NISOLI E, CARRUBA M O. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action[J]. Obesity Revs, 2000, 1(2): 127-139.

二级参考文献49

  • 1钱伯初.肥胖动物模型的制备原理和方法[J].中国药理学通报,1993,9(1):75-76. 被引量:81
  • 2陈奇,嘉红云,龙玲玲.盐酸西布曲明对单纯性肥胖大鼠血脂和心功能改变的影响[J].海南医学院学报,2005,11(2):98-101. 被引量:2
  • 3廖丽萍,陈洲,刘晓红,刘礼斌.肥胖大鼠下丘脑前增食欲素原表达降低[J].基础医学与临床,2006,26(12):1375-1376. 被引量:3
  • 4George A, Bray GA.Medicinal strategies in thes treatment of obesity [ J] .Nature, 2000, 404(6): 672~677
  • 5靳晓红.减肥药千万别乱吃.环球时报,2002,07:22
  • 6Luque CA, Rey JA.The discovery and status of Sibutramine as an anti-obesity drug [ J] .Eur J Pharmacol, 2002,440 (2~3): 119.128
  • 7Mcneely W, Goa KL.Sibutramine: areview of its contribution to the management of obesity [J] .Drugs, 1998, 56(6): 1093~1124
  • 8[1]T Radhakrishna.LC method for the determination of assay and purity of sibutramine hydrochloride and its enantiomers by chiral chromatography[J].J Pharma and Biome Analy,2000,22:627.
  • 9Yang JW. ( Sepracor Inc. ) Methods and composition for treating depression and other disorders using optically pure ( + ) sibutramine.PCT Int. Appl. WO 9400047 ( Cl. A51K31/45) ,06 Jan 1994,US Appl. 903034,23 Jun 1992 ;40pp.
  • 10Yang JW. ( Sepracor Inc. ) Pharnlaceutical compositions for treating depression and other cerebral disorders containing optically pure( - )sibutramine. PCT Int. Appl. WO 9400114( Cl. A61 K31/135 ) ,06 Jan1994, US Appl. 903040,23 Jun 1992 ;40pp.

共引文献63

同被引文献59

引证文献4

二级引证文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部